Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Key enzyme found to influence immune aging and B cell production

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, however, thanks to a new study in GeroScience.

17 Apr 2025

Study offers a potential new strategy to improve treatment responses in multiple myeloma patients

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment responses in multiple myeloma patients by blocking a protein that plays a key role in drug resistance.

15 Apr 2025

Multiple myeloma care improved using innovative optical genome mapping

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma.

15 Apr 2025

Surface light chain expression in B-ALL after myeloma treatment: A unique case report

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence.

10 Apr 2025

Breakthrough study links NSD2 gene to plasma cell identity in myeloma

A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma."

2 Apr 2025

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells.

1 Apr 2025

Waist circumference identified as a stronger cancer risk marker in men

Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established risk factors for many types of cancer. However, new research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) and published in The Journal of the National Cancer Institute shows that waist circumference (WC) is a stronger risk marker than BMI for developing obesity-related cancers in men, but not women.

24 Mar 2025

New supercharged CAR-T cell therapy shows promise against resistant cancers

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.

10 Mar 2025

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025

Anti-malarial drug pyronaridine could be repurposed to treat cancer

Can a drug that's used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have secured a patent for the anti-malarial drug pyronaridine to do just that. Pyronaridine has been used to treat the mosquito-borne infectious disease for over 30 years.

3 Mar 2025

Future of cancer coverage for women federal firefighters uncertain under Trump

It took nearly three years to win presumptive workers' compensation coverage for breast, cervical, and other cancers that firefighters who work for federal agencies may develop because of hazardous exposures on the job.

28 Feb 2025

Study unravels the complex interplay of the UPS in cancer development and treatment

A new review published in Genes & Diseases explores the pivotal role of the ubiquitin-proteasome system (UPS) in regulating the tumor microenvironment (TME) and driving cancer progression. The study provides novel insights into how ubiquitination and deubiquitination impact tumor cells, immune responses, and potential therapeutic strategies for cancer treatment.

24 Feb 2025

Development of lymphoma following CAR-T cell therapy

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

22 Feb 2025

Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

17 Feb 2025

New gene modification enhances CAR-T cell effectiveness against cancer

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for an extended period, potentially reducing the chance of cancer recurring.

7 Feb 2025

New findings could make off-the-shelf CAR T cell therapy a reality

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets on the surface of the cancer cell.

31 Jan 2025

Pomalidomide shows promise in enhancing immune responses in myeloma

A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma."

23 Jan 2025

Novel materials show promise in treating multiple myeloma bone lesions

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

15 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025